GlassScriptPhysician profile
Benjamin Anderson Hester
NPI 1538225206
$2,642.59
in general payments reported to CMS, 2019-2025
29 companies · $22.95 in 2025
The $22.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $207 · 2021: $183 · 2022: $825 · 2023: $706 · 2025: $22.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.28 | 2019-2023 | Ozempic, Tresiba, Rybelsus |
| Abbvie INC. | $267.84 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.21 | 2021-2023 | |
| Amgen INC. | $185.70 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $184.91 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $162.21 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $132.23 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $128.47 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $107.83 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.71 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.55 | 2019-2023 | Synjardy, Jardiance, Glyxambi |
| Daiichi Sankyo INC. | $70.40 | 2019-2023 | Injectafer |
| Pfizer INC. | $68.99 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.47 | 2022 | |
| Astellas Pharma US INC | $53.96 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $51.18 | 2019-2022 | |
| Exact Sciences Corporation | $42.63 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $42.03 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $41.28 | 2022-2023 | Eliquis |
| Amarin Pharma, INC. | $35.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $33.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.32 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $25.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.82 | 2019 | |
| Intuity Medical INC | $17.56 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.94 | 2019 | |
| Boston Scientific Corporation | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.